Compare Ford Motor Company (F) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Neurocrine Biosciences Inc — how do they compare? Ford Motor Company trades at $12.3 (market cap $48.33B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Ford Motor Company is far larger — about 3.3× Neurocrine Biosciences Inc's market cap, and Ford Motor Company pays a 4.95% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and Neurocrine Biosciences Inc for 23 Days on average.
| F | NBIX | |
|---|---|---|
Market Cap | $48.33B | $14.60B |
Volume | 33,572,159 | 1,075,694 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $185.50 |
52-Week Low | $11.21 | $123.10 |
Typical Hold Time | 104 Days | 23 Days |
Enterprise Value | $180.29B | $14.61B |
Dividend Yield | 4.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.25, down 0.2% with bearish technical signals. The company reported mixed quarterly results, beating Q1 and Q2 2026 EPS estimates but missing Q4 2025. Despite $187.3B revenue in 2025, net income was -$8.18B with negative margins. Analyst consensus is mixed with 38% buy ratings and a $15.90 price target. Recent news highlights sales declines and production challenges, though the company maintains strong cash flow from operations.
Ford faces significant headwinds including declining sales, negative profitability, and high debt levels. The stock offers value with low P/E (11.21) and P/S (0.26) ratios, but execution risks and competitive pressures from Asian automakers pose challenges. The dividend provides income support, but investors should weigh fundamental weaknesses against valuation appeal.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
